Tekmira Says Pipeline on Track Heading into Q4; Holds Course on Alnylam Litigation | GenomeWeb

By Doug Macron

As Tekmira Pharmaceuticals this week released its third-quarter financial results, the company's top official provided an update on the firm's research-and-development efforts, stating that it's on track to report phase I data on its lead cancer drug by year end and begin human trials of an Ebola treatment in early 2012.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.